Who Paid My Doc
Javier Sosa Faria
Juana Diaz, PR Medical Doctor
NPI 1205911203 CMS profile 1310615
15 Calle Luis Felipe Dessus, Suite 101, Juana Diaz, PR 00795
General payments
$1,557
Research payments
$7,137
Ownership & investment interest
$0
Research they led as principal investigator
$464,716
Through program year 2025, Javier Sosa Faria of Juana Diaz, PR is reported in the CMS Open Payments database as having received $1,557 across 10 general payments and $7,137 in research payments paid to them. Separately, studies naming them as principal investigator received $464,716 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,498 | 7 | |
| 2023 | General | $26 | 1 | |
| 2023 | Research | $795 | 1 | |
| 2022 | General | $19 | 1 | |
| 2022 | Research | $6,329 | 1 | |
| 2021 | General | $13 | 1 | |
| 2020 | Research | $13 | 1 |
Beside peers
- Javier Sosa Faria
- Puerto Rico median
- Middle half of Puerto Rico
- National median
In program year 2025, general payments to Javier Sosa Faria were reported at $1,498. Among 6,407 Puerto Rico profiles paid that year, the median was $138 and the middle half received between $51 and $379.
Show as a table
| Year | Javier Sosa Faria | Puerto Rico median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $136 | $56–$387 | $163 |
| 2020 | $0 | $80 | $35–$213 | $114 |
| 2021 | $13 | $110 | $37–$313 | $132 |
| 2022 | $19 | $131 | $52–$362 | $149 |
| 2023 | $26 | $127 | $50–$377 | $160 |
| 2024 | $0 | $141 | $56–$375 | $164 |
| 2025 | $1,498 | $138 | $51–$379 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
169
Drug cost
$9,793
Branded share of claims
60.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Santyl Collagenase Clostridium Hist. | Brand | 27 | $8,268 | |
| Ciprofloxacin Hcl | Generic | 38 | $422 | |
| Clotrimazole-Betamethasone Clotrimazole/Betamethasone Dip | Brand | 13 | $404 | |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | Brand | 62 | $346 | |
| Clindamycin Hcl | Generic | 15 | $281 | |
| Tramadol Hcl | Generic | 14 | $72 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 7,210 Part D prescribers listed as General Practice; they describe a distribution and say nothing about conduct.
Records
13 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.